Molgramostim biosimilar (Reponex Pharmaceuticals)

莫拉司亭生物类似药 (Reponex Pharmaceuticals)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMolgramostim biosimilar (Reponex Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulants
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsVaricose Ulcer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesReponex Pharmaceuticals As
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsVaricose Ulcer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A